News & Views | Published:

Epigenetics

Targeting leukemia on the DOT

Nature Chemical Biology volume 7, pages 663665 (2011) | Download Citation

A combination of chemical and genetic approaches has established a proof of concept in mouse models—with strong mechanistic underpinning—indicating that targeting the aberrantly recruited histone methyltransferase activity of DOT1L has therapeutic potential in aggressive leukemias driven by MLL fusion genes.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Nat. Rev. Cancer 7, 823–833 (2007).

  2. 2.

    & Nat. Med. 17, 330–339 (2011).

  3. 3.

    et al. N. Engl. J. Med. 363, 2424–2433 (2010).

  4. 4.

    et al. Cancer Cell 20, 25–38 (2011).

  5. 5.

    et al. Nat. Genet. 41, 521–523 (2009).

  6. 6.

    et al. Nat. Genet. 42, 181–185 (2010).

  7. 7.

    et al. Genes Dev. 22, 3403–3408 (2008).

  8. 8.

    & Chem. Biol. 17, 561–577 (2010).

  9. 9.

    , & Nat. Rev. Drug Discov. 8, 724–732 (2009).

  10. 10.

    , , , & Cell 112, 711–723 (2003).

  11. 11.

    et al. Cancer Cell 20, 53–65 (2011).

  12. 12.

    et al. Cancer Cell 20, 66–78 (2011).

  13. 13.

    et al. Nat. Chem. Biol. 7, 566–574 (2011).

Download references

Acknowledgements

The authors wish to acknowledge B. Matijssen for assistance with Figure 1b.

Author information

Affiliations

  1. Jon Travers and Paul Workman are in the Signal Transduction and Molecular Pharmacology Team, Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK.

    • Jon Travers
    •  & Paul Workman
  2. Julian Blagg is in the Medicinal Chemistry Team, Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK.

    • Julian Blagg

Authors

  1. Search for Jon Travers in:

  2. Search for Julian Blagg in:

  3. Search for Paul Workman in:

Competing interests

P.W. and J.B. are employees of and J.T. is a student of the Institute of Cancer Research. P.W. is also associated with Chroma Therapeutics and Nextech Invest Ltd.

Corresponding author

Correspondence to Paul Workman.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nchembio.661

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing